Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02362035
Title ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

hematologic cancer

Therapies

Acalabrutinib

Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.